Andrew Hitchings, Emma Baker, and Teck Khong examine how drug companies maximise profits after patents expire and show why regulatory agencies, policy makers, and prescribers need to be alert to the use of these techniques
No takes yet. Share an insight, caveat, or question.
Hitchings et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: